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Background
In this module, you will learn about the history of tuberculosis (TB), how TB is spread from person to 
person (transmission), and how TB disease develops in the body (pathogenesis). Our understanding of 
the transmission and pathogenesis of TB has guided us in developing strategies for controlling the spread 
of TB and for treating latent TB infection (LTBI) and TB disease. As a public health worker, it is important to 
understand these concepts so that you can educate the patients you serve.
Note: The Self-Study Modules on Tuberculosis are a series of educational modules designed to provide information about TB in a self-
study format. The target audiences include outreach workers, nurses, physicians, administrators, health educators, and students from 
a variety of settings.  The Modules should not be used as a substitute for guidelines and should not be  used for patient care decisions. 
Objectives
After working through this module, you will be able to
1. Describe the history of TB.
2. Explain how TB spreads (transmission).
3. Define drug-resistant TB. 
4. Explain the difference between LTBI and TB disease.
5. Explain how LTBI and TB disease develop (pathogenesis).
6. Describe the classification system for TB.
define
explain
list
describe
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Doctor reviewing a chest x-ray.
New Terms
New terms introduced in this module are included below. These terms appear in bold in the module text.
AIDS—acquired immunodeficiency syndrome, a 
condition in which the immune system is weakened 
and therefore less able to fight certain infections and 
diseases; AIDS is caused by infection with the human 
immunodeficiency virus (HIV)
alveoli—the small air sacs of the lung that are at the end 
of the airway; when droplet nuclei reach these air sacs, TB 
infection begins
corticosteroid—a type of steroid, either natural or man-
made, often used to treat arthritis, certain allergies, or 
other immune disorders
diabetes mellitus—a disease in which blood glucose 
levels are above normal; diabetes can increase 
susceptibility to some infectious diseases, including TB
disseminated TB—TB disease that occurs when tubercle 
bacilli enter the bloodstream or lymph system and are 
carried to all parts of the body where they grow and 
cause disease in multiple sites, e.g., miliary TB
droplet nuclei—very small droplets (1 to 5 microns 
in diameter) containing M. tuberculosis  that may be 
expelled when a person who has infectious TB coughs, 
sneezes, speaks, or sings; the droplets can remain 
suspended in the air for several hours, depending on  
the environment 
drug-resistant TB—TB caused by M. tuberculosis   
organisms that are able to grow in the presence of a 
particular drug; TB that is resistant to at least one  
anti-TB drug
extensively drug-resistant TB (XDR TB)—a type  
of MDR TB that is resistant to isoniazid and rifampin,  
plus resistant to any fluoroquinolone and at least one 
of three injectable anti-TB drugs (such as amikacin, 
kanamycin, or capreomycin)
extrapulmonary TB—TB disease that occurs in places 
other than the lungs, such as the lymph nodes, the 
pleura, the brain, the kidneys, or the bones; most types  
of extrapulmonary TB are not infectious
first-line TB treatment drugs—of the approved 
drugs to treat TB, isoniazid, rifampin, ethambutol, and 
pyrazinamide are considered the first-line anti-TB drugs; 
they form the core of a standard treatment regimen. 
They are considered “first-line” because together they 
constitute the most powerful, least expensive, and most 
tolerable treatment regimen.
fluoroquinolones—a class of synthetic broad-spectrum 
antibacterial drugs. Examples of fluoroquinolones used 
to treat TB are levofloxacin and moxifloxacin.
HIV—human immunodeficiency virus, the virus that 
causes AIDS
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immune system—cells and tissues in the body that 
protect the body from foreign substances
immunosuppressive therapy—therapy that suppresses, 
or weakens, the immune system
infectious—capable of spreading infection; a person 
who has infectious TB disease expels droplets containing 
M. tuberculosis into the air when he or she coughs, 
sneezes, speaks, or sings
interferon-gamma release assay (IGRA)—a type  
of blood test that measures a person’s immune reactivity 
to M. tuberculosis  
latent TB infection (LTBI)—refers to the condition when a 
person is infected with M. tuberculosis  but  
does not have TB disease. Persons with LTBI carry the  
M. tuberculosis organism that causes TB, but they do not 
have TB disease symptoms, do not feel sick, and cannot 
spread TB germs to others. Most persons with LTBI 
have a positive result to the tuberculin skin test or to an 
interferon-gamma release assay.
Mantoux tuberculin skin test (TST)—a method of testing 
for TB infection; a needle and syringe are used to inject 
0.1 ml (5 tuberculin units) of purified protein derivative 
(PPD) tuberculin solution between the layers of the 
skin (intradermally), usually on the forearm; the reaction 
to this test, usually a small swollen area (induration), 
is measured 48 to 72 hours after the injection and is 
interpreted as positive or negative depending on the 
size of the reaction and the patient’s risk factors for TB; 
the routine methodology for tuberculin skin testing 
worldwide; supersedes all older methods
miliary TB—a type of disseminated TB disease that 
occurs when tubercle bacilli enter the bloodstream and 
are carried to all parts of the body, where they grow and 
cause disease in multiple sites; the chest x-ray of patients 
with miliary TB often looks like millet seeds scattered 
throughout the lung
mono-resistant TB—TB that is resistant to one TB 
treatment drug
multidrug-resistant TB (MDR TB)—TB that is resistant to 
at least the drugs isoniazid and rifampin; MDR TB is more 
difficult to treat than drug-susceptible TB
mycobacteria—a group of bacteria that can cause a 
variety of diseases
Mycobacterium avium-complex—a nontuberculous 
mycobacteria (NTM) that can cause opportunistic 
infections in immunocompromised persons; often 
disseminated infections
Mycobacterium bovis—a type of tuberculous 
mycobacteria that can cause a disease similar to TB; 
usually infects cows, but it can infect other mammals 
including humans. Before the pasteurization of milk 
became common practice, these mycobacteria were 
often spread to humans through contaminated milk; in 
the United States today, M. bovis rarely affects humans.
Mycobacterium tuberculosis complex—the  
M. tuberculosis complex includes seven other TB-causing 
mycobacteria: M. bovis, M. africanum, M. microti,  
M. canetti, M. caprae, M. pinnipedii, and M. mungi. 
These mycobacteria are sometimes called tuberculous 
mycobacteria since they can cause TB disease or other 
diseases very similar to TB. Mycobacterium tuberculosis 
is the most common cause of TB in humans; it is 
sometimes called the tubercle bacillus. 
nontuberculous mycobacteria—mycobacteria that do 
not cause TB disease and are not usually spread from 
person to person; one example is M. avium-complex
pathogenesis—how an infection or disease develops  
in the body
poly-resistant TB—TB that is resistant to at least two TB 
treatment drugs (but not both isoniazid and rifampin, i.e., 
it is not the same as MDR TB)
primary drug-resistance—drug-resistance  
caused by person-to-person transmission of drug-
resistant organisms
pulmonary TB—TB disease that occurs in the lungs 
typically causing a cough and an abnormal chest x-ray; 
pulmonary TB is usually infectious if untreated. Most TB 
cases reported in the United States are pulmonary cases.
Module 1— Transmission and Pathogenesis of Tuberculosis4
secondary drug-resistance—also referred to as acquired 
drug-resistance; develops during TB treatment, either 
because the patient was not treated with the appropriate 
treatment regimen or because the patient did not follow 
the treatment regimen as prescribed
silicosis—a lung disease caused by inhaling silica dust, 
which is released by breaking rocks or is used in the 
production of glass and ceramics; occurs most often in 
mining, construction, and foundry workers
transmission—the spread of an organism, such as M. 
tuberculosis, from one person to another. The probability 
of transmission depends on the contagiousness of the 
patient, the type of environment, the length of exposure, 
and the susceptibility of the exposed individual.
tubercle bacilli—another name for the Mycobacterium 
tuberculosis organisms that cause TB disease
tuberculin skin test (TST)—a test used to detect TB 
infection (see Mantoux tuberculin skin test)
tumor necrosis factor-alpha (TNF-alpha) antagonists, 
inhibitors, or blockers— medications used to treat 
inflammatory or autoimmune diseases such as 
rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, 
and juvenile rheumatoid arthritis 
x-ray—a test that produces images of the inside the 
body. x-ray beams pass through the body and are 
absorbed in different amounts depending on the density 
of the material they pass through. Dense materials, such 
as bone, show up as white on x-rays. Air in the lungs 
shows up as black. Fat and muscle appear as varying 
shades of gray.
New Terms (continued)
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MODULE
History of TB
Tuberculosis — a disease also historically known as consumption, wasting disease, and the white 
plague — has affected humans for centuries. Until the mid-1800s, people thought that tuberculosis, or 
TB, was hereditary or attributable to an unhealthy life. They did not realize that it could be spread from 
person to person through the air. Also, until the 1940s and 1950s, there was no antibiotic treatment for 
TB. For many people, a diagnosis of TB was a slow death sentence. 
TB has affected humans for centuries. 
In 1865 a French surgeon, Jean-Antoine Villemin, showed that TB was contagious, and in 1882 a 
German scientist named Robert Koch discovered the bacterium that causes TB. Yet, half a century 
passed before drugs were discovered that could treat TB. Until then, many people with TB went to 
sanatoriums, which were special rest homes where they followed a prescribed routine every day. No 
one knows whether sanatoriums really helped people with TB; and even if they did, many people with 
TB could not afford to go to a sanatorium, and they died at home. 
A breakthrough came in 1943. An American scientist, Selman Waksman and one of his assistants,  
Albert Schatz, discovered a drug that could kill TB bacteria. Between 1943 and 1952, two more drugs 
were found. After these discoveries, many people with TB were treated, and the death rate for TB in the 
United States dropped dramatically. Each year, fewer and fewer people died from TB. 
In the 1940s and 1950s, drugs were discovered to treat TB.  
After this, the death rate for TB in the United States  
dropped dramatically, and fewer and fewer people died from TB.
By the mid-1970s, most TB sanatoriums in the United States had closed. As cases and deaths declined, 
people began to hope that TB could be eliminated from the United States, like polio and smallpox. 
In the mid-1980s, however, TB cases started increasing again in the United States. This rise in cases has 
been attributed to several factors, which are discussed further in Module 2, Epidemiology of Tuberculosis. 
Because of the rise in TB, federal and state funding for TB control was increased. The funding helped 
health departments and other organizations successfully boost their efforts to prevent and control 
the disease. Since 1993, TB cases in the United States overall have been steadily declining. However, 
prevention and control efforts must be maintained, since TB continues to be reported in every state 
throughout the country. Moreover, even today, TB can be fatal if not treated in time. A timeline of 
major events in the history of TB is shown in Figure 1.1.
In the mid-1980s, the number  
of  TB cases started increasing again.
Since 1993, due to enhanced prevention  
and control efforts, the number of  
TB cases has been declining.
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1800 1820 1840 1860 1880 1900 1920 1940 1960 1980 2000
1884: First TB sanatorium is 
established in the United States
1865: Jean-Antoine 
Villemin shows that 
TB is contagious
1943: Streptomycin, 
a drug used to treat TB, 
is discovered
By the mid 1970s, most 
TB sanatoriums in the 
United States had closed
By 1993, TB cases started declining 
again due to increased federal funding 
and enhanced  TB control efforts
1882: Robert Koch 
discovers M. tuberculosis, 
the bacterium that causes TB
1943–1952: Two more 
drugs are discovered 
to treat TB
In the mid-1980s, 
there was an unexpected 
rise in TB cases
Figure 1.1 Timeline of major events in the history of TB.
Figure 1.1 Timeline illustrating the major events in the history of TB from 1800-2000.  
1865: Jean-Antoine Villemin shows that TB is contagious  1882: Robert Koch discovers M. tuberculosis, the 
bacterium that causes TB  1884: First TB sanatorium is established in the United States  1943: Streptomycin, a 
drug used to treat TB, is discovered  1943–1952: Two more drugs are discovered to treat TB  By the mid-1970’s 
most TB sanatoriums in the United States had closed  In the mid -1980’s there was an unexpected rise in TB 
cases  By 1993, TB cases started declining again due to increased federal funding and enhanced TB control efforts
Study Question 1.1
1.1 In what year was each of the following discoveries made?
A. TB was shown to be contagious  
B. The bacterium that causes TB was discovered
C. The first drug that could kill TB bacteria was discovered
Answers to study questions are on pages 26–30
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MODULE
Transmission
Mycobacteria are a group of bacteria that can cause a variety of diseases. Some mycobacteria are grouped 
as Mycobacterium tuberculosis complex because they cause TB or diseases similar to TB. In the United States, 
the vast majority of TB cases are caused by an organism called Mycobacterium tuberculosis. M. tuberculosis  
organisms are also called tubercle bacilli. Other mycobacteria that can cause human tuberculosis disease 
include M. bovis, M. africanum, M. microti, and M. canetti.
An organism called Mycobacterium tuberculosis causes TB.
Mycobacteria that cause diseases that can be confused with TB are often called nontuberculous 
mycobacteria. Nontuberculous mycobacteria can also confuse laboratory tests used to diagnose TB (for 
more information on tests used to diagnose TB, refer to Module 3, Targeted Testing and the Diagnosis of Latent 
Tuberculosis Infection and Tuberculosis Disease).  One common type of nontuberculous mycobacteria is the  
M. avium-complex. Nontuberculous mycobacteria are not usually spread from person to person. 
TB spreads person to person through the air (Figure 1.2). When a person with infectious TB disease (TB 
that can be spread) coughs, sneezes, speaks, or sings, tiny particles containing M. tuberculosis  may be 
expelled into the air. These particles, called droplet nuclei, are about 1 to 5 microns in diameter— 
less than 1/5000 of an inch. Droplet nuclei can remain suspended in the air for several hours, depending 
on the environment.
TB spreads person to person through the air.
If another person inhales air that contains these droplet nuclei, infection may result from this transmission. 
Transmission is the spread of an organism such as M. tuberculosis  from one person to another.
Transmission is the spread of an organism such as  
M. tuberculosis from one person to another.
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Figure 1.2 Transmission of TB. TB spreads person to person through the air.  
The dots in the air represent droplet nuclei containing tubercle bacilli.
An illustration of droplet nuclei containing tubercle bacilli spreading from one person to  
another through the air.
Not everyone who is exposed to an infectious TB patient becomes infected with M. tuberculosis. 
The probability that TB will be transmitted depends on four factors:
zz Infectiousness of the TB patient
zz Environment in which the exposure occurred
zz Frequency and duration of the exposure
zz Susceptibility (immune status) of the exposed individual
Not everyone who is exposed to an  
infectious TB patient becomes infected.
Persons who spend a lot of time in enclosed spaces with people who have infectious TB disease are the 
most likely to be infected with M. tuberculosis. These persons, or contacts, may include family members, 
friends, roommates, or coworkers. Refer to Module 8, Contact Investigations for Tuberculosis, for more 
information on contact investigations.
The best way to stop transmission is to isolate infectious persons and to start giving them the standard 
TB treatment as soon as possible. The length of time required for a TB patient to become noninfectious 
after starting TB therapy varies and cannot be determined with certainty. However, once the standard 
TB therapy is started, and as long as the patient follows the prescribed treatment regimen, the 
infectiousness of the TB patient can rapidly decline. For more information on infectiousness, refer to 
Module 5, Infectiousness and Infection Control.
The best way to stop transmission is to isolate infectious  
persons and to start giving them the standard  
TB treatment as soon as possible.
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Drug-resistant TB
Drug-resistant TB is caused by M. tuberculosis organisms that are resistant to the drugs normally used  
to treat the disease. This means those drugs can no longer kill the bacteria. 
Drug-resistant TB is caused by M. tuberculosis organisms that are resistant  
to the drugs normally used to treat the disease.
Drug-resistant TB can be mono-resistant if the tubercle bacilli are resistant to any one TB treatment drug, 
or poly-resistant if resistant to at least two TB drugs (but not both isoniazid and rifampin). Multidrug-
resistant TB (MDR TB) means that the tubercle bacilli are resistant to at least isoniazid and rifampin, the 
two best first-line TB treatment drugs. Extensively drug-resistant TB (XDR TB) means that the tubercle 
bacilli are resistant to isoniazid and rifampin, plus resistant to any fluoroquinolone and at least one of 
three injectable anti-TB drugs (such as amikacin, kanamycin, or capreomycin).
Drug-resistant TB can be transmitted the same way as drug-susceptible TB. However, drug-resistant TB is 
more difficult to treat because the bacilli can survive in a patient’s body even after they start treatment 
with the first-line TB treatment drugs*. Also, it may take longer to diagnose drug-resistant TB. These 
patients may be infectious for a longer period of time. This may result in more people being infected.
Drug-resistant TB can be caused in two different ways: primary and secondary (acquired). Person-
to-person transmission of drug-resistant organisms causes primary resistance. Secondary resistance 
develops during TB treatment, either because the patient was not treated with an appropriate regimen 
or because the patient did not follow the treatment regimen as prescribed. In other words, if patients 
do not take all of their pills, or if they do not take their pills as often as prescribed, they could develop 
secondary drug-resistant TB. Patients with TB should be closely monitored to see if they are responding 
to treatment and they should remain in isolation until it is shown that they are no longer infectious.
Diagnosis and treatment of drug-resistant TB is discussed in more detail in Module 3, Targeted Testing  
and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease and Module 4, Treatment of Latent 
Tuberculosis Infection and Tuberculosis Disease.
Infectiousness and the transmission of TB is discussed in more detail in Module 5, Infectiousness  
and Infection Control.
* Drug-susceptible TB can be treated with the first-line TB treatment drugs.
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Study Questions 1.2–1.6
1.2 What organism causes TB? What are four other tuberculous mycobacteria? 
1.3 How is TB spread? Select one. 
A. TB spreads person to person through blood
B. TB spreads person to person through the air
C. TB spreads person to person through touch
D. All of the above
1.4 The probability that TB will be transmitted depends on what four factors?
1.5 What is drug-resistant TB?
1.6 What is the difference between primary and secondary drug resistance?
Answers to study questions are on pages 26–30
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MODULE
Pathogenesis
When a person inhales air that contains droplet nuclei containing M. tuberculosis, most of the larger 
droplets become lodged in the upper respiratory tract (the nose and throat), where infection is unlikely 
to develop. However, smaller droplet nuclei may reach the small air sacs of the lung (the alveoli), where 
infection may begin (Figure 1.3). The following section describes the pathogenesis of TB (the way TB 
infection and disease develop in the body).
Infection may begin when droplet nuclei reach the alveoli.
In the alveoli, some of the tubercle bacilli are killed, but a few multiply in the alveoli and enter the 
lymph nodes and bloodstream and spread throughout the body. Bacilli may reach any part of the body, 
including areas where TB disease is more likely to develop. These areas include the upper portions of 
the lungs, as well as the kidneys, the brain, and bone. Within 2 to 8 weeks, however, the body’s immune 
system usually intervenes, halting multiplication and preventing further spread. The immune system is 
the system of cells and tissues in the body that protect the body from foreign substances. At this point, 
the person has latent TB infection (LTBI).
Nose 
Mouth 
Trachea 
Pleural 
space 
Bronchi 
Larynx 
Bronchioles 
Alveoli 
Figure 1.3 The lungs and the alveoli.
Illustration of the human respiratory system including the nose, mouth, 
larynx, trachea, bronchi, pleural space, bronchioles, and the alveoli.
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Latent TB Infection (LTBI)
Latent TB infection (LTBI) means that tubercle bacilli are in the body, but the body’s immune system is 
keeping the bacilli suppressed and under control. The immune system does this by producing special 
immune cells that surround the tubercle bacilli. The cells form a shell that acts as a barrier and keeps the 
bacilli contained.
LTBI means that tubercle bacilli are in the body,  
but the immune system is keeping 
 the bacilli suppressed and under control.
LTBI is detected by the Mantoux tuberculin skin test (TST) or an interferon-gamma release assay (IGRA). 
Most people with LTBI have a positive TST or IGRA result. Module 3, Targeted Testing and the Diagnosis of 
Latent Tuberculosis Infection and Tuberculosis Disease, discusses the TST and IGRAs in more detail.
LTBI is detected by the tuberculin skin test (TST) or an  
interferon-gamma release  assay (IGRA).
People who have LTBI, but not TB disease, are NOT contagious —they do not feel sick and they cannot 
spread the infection to other people. Most of these people have a normal chest x-ray. It is important 
to remember that LTBI is not a case of TB. Table 1.1 describes the major similarities and differences 
between LTBI and TB disease.
People with LTBI are NOT contagious.
Table 1.1 – LTBI vs. TB Disease.
Person with Latent TB Infection (LTBI) Person with TB Disease (in the lungs)
Has a small number of TB bacteria in his or her body  
that are alive, but under control  
Has a large number of active TB bacteria in his or her body 
Cannot spread TB bacteria to others May spread TB bacteria to others
Does not feel sick, but may become sick if the bacteria 
become active in his or her body
May feel sick and may have symptoms such as a cough, 
fever, or weight loss
Tuberculin skin test or interferon-gamma release assay 
results usually positive
Tuberculin skin test or interferon-gamma release assay 
results usually positive
Chest x-ray usually normal Chest x-ray usually abnormal
Sputum smears and cultures negative Sputum smears and cultures may be positive
Should consider treatment for LTBI to prevent TB disease Needs treatment for TB disease
Does not require respiratory isolation May require respiratory isolation
Not a case of TB A case of TB
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Study Questions 1.7–1.9
1.7 When a person inhales droplet nuclei containing M. tuberculosis, where 
do the droplet nuclei go?
1.8 After the tubercle bacilli reach the small air sacs of the lung (the alveoli), 
what happens to the tubercle bacilli?
1.9 In people with LTBI (but not TB disease), how does the immune system 
keep the tubercle bacilli under control?
Answers to study questions are on pages 26–30
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Study Questions 1.10–1.11
1.10 How is LTBI detected?  
1.11 What are the major similarities and differences between LTBI and  
TB disease? List characteristics of each.
Answers to study questions are on pages 26–30
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Case Study 1.1
A 30-year-old man visits the health department for a TST because he 
is required to have one before starting his new job as a health care 
worker. He has an 18 mm positive reaction to the TST.  He has no 
symptoms of TB, and his chest x-ray findings are normal.
z Should this be considered a case of TB? Why or why not?
z Should this man be considered infectious? 
Answers to case study questions are on page 31
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TB Disease
Some people with LTBI develop TB disease later. TB disease develops when the immune system 
cannot keep the tubercle bacilli under control and the bacilli begin to multiply rapidly. The risk that  
TB disease will develop is higher for some people than for others. Figure 1.4 shows the pathogenesis 
of LTBI and TB disease.
TB disease develops when the immune system cannot keep the  
tubercle bacilli under control and the bacilli begin to multiply rapidly.
TB disease can develop very soon after infection or many years after infection. In the United States,  
unless treated, about 5% of the people who have recently been infected with M. tuberculosis  will 
develop TB disease in the first year or two after infection. Another 5% will develop TB disease later in 
their lives. In other words, about 10% of all people with normal immune systems who have LTBI will 
develop TB disease at some point in their lives. The remaining 90% will remain free of TB disease for 
the rest of their lives. However, some conditions can greatly increase the risk of developing TB disease.
TB disease can develop very soon  
after infection or many years after infection.
Figure 1.4 Pathogenesis of LTBI and TB disease.
1
area of detail 
for boxes 
2, 4, and 5 
An illustration of droplet nuclei containing 
tubercle bacilli being inhaled, entering the 
lungs, and traveling to the alveoli.
Droplet nuclei containing tubercle bacilli 
are inhaled, enter the lungs, and travel  
to the alveoli. 
2 bronchioleblood vessel
tubercle bacilli
alveoli
An illustration of tubercle bacilli 
multiplying in the alveoli. 
Tubercle bacilli multiply in the alveoli.
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Figure 1.4 Pathogenesis of LTBI and TB disease. (Continued)
3 brain
lung
kidney
bone
An illustration of areas where TB disease is more likely 
to develop, such as the lungs, kidneys, brain, or bone. 
A small number of tubercle bacilli enter 
the lymph nodes and bloodstream and 
spread throughout the body. The tubercle 
bacilli may reach any part of the body, 
including areas where TB disease is 
more likely to develop (such as the lungs, 
kidneys, brain, or bone).
4 special immune 
cells form a 
barrier shell 
(in this example, 
bacilli are in 
the lungs)
An illustration of a macrophage 
surrounding the tubercle bacilli. 
Within 2 to 8 weeks, the immune 
system produces special immune cells 
called macrophages that surround the 
tubercle bacilli. The cells form a barrier 
shell that keeps the bacilli contained 
and under control (LTBI).
5 shell breaks down and 
tubercle 
bacilli escape 
and multiply 
(in this example, 
TB disease 
develops in 
the lungs)
An illustration of tubercle bacilli rapidly 
multiplying, progressing from LTBI to TB disease.
If the immune system cannot keep the 
tubercle bacilli under control, the bacilli 
begin to multiply rapidly (TB disease). 
This process can occur in different places 
in the body, such as the lungs, kidneys, 
brain, or bones (see diagram in box 3).
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Because about half the risk of developing TB disease is concentrated in the first 2 years after infection, 
it is important to detect new infection early. People with LTBI should be offered treatment to prevent 
them from getting sick with TB disease. This is discussed in Module 4, Treatment of Latent Tuberculosis 
Infection and Tuberculosis Disease. Thus, detecting new infection early helps prevent new cases of TB. 
Table 1.1 shows the major similarities and differences between LTBI and TB disease.
The risk of developing TB disease is highest 
 in the first 2 years after infection.
Some conditions increase the risk that LTBI will progress to disease. These conditions increase the risk 
by negatively impacting the ability of the body’s immune system to control the spread of tubercle 
bacilli. The risk may be about 3 times higher (as with diabetes) to more than 100 times higher (as with 
human immunodeficiency virus [HIV] infection) for people who have these conditions than for those 
who do not. Some of these conditions that increase the risk are
zz Infection with HIV
zz History of untreated or inadequately treated TB disease
zz Recent TB infection (within the past 2 years)
zz Abusing drugs or alcohol or smoking cigarettes 
zz Receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) 
antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, 
or immunosuppressive drug therapy following organ transplantation
zz Silicosis
zz Diabetes mellitus
zz Chronic renal failure
zz Certain types of cancer (e.g., leukemia, cancer of the head, neck, or lung)
zz Certain intestinal conditions
zz Low body weight
For definitions of some of these terms, please see the Modules 1-5 Glossary or the New Terms  
section at the beginning of this module.
Some conditions increase the risk  
that LTBI will progress to disease.
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Transmission and Pathogenesis of TB
When a person has a weakened immune system, their body may not be able to control the 
multiplication and spread of tubercle bacilli. For this reason, people who are infected with both  
M. tuberculosis and HIV are much more likely to develop TB disease than people who are infected only 
with M. tuberculosis. The risk of developing TB disease is 7% to 10% each year for people who are infected 
with both M. tuberculosis and HIV (if the HIV is not being treated), whereas it is10% over a lifetime for 
people infected only with M. tuberculosis. For people with LTBI and diabetes, the risk is 3 times greater, or 
about 30% over a lifetime (Figure 1.5). 
People who are infected with both M. tuberculosis and HIV  
are much more likely to develop TB disease than people  
who are infected only with M. tuberculosis.
TB infection 
and no risk factors
(about 10% over a lifetime)
For people with TB infection and 
 no risk factors, the risk is about 5% 
 in the first 2 years after infection 
 and about 10% over a lifetime.
TB infection
and diabetes
(about 30% over a lifetime)
For people with TB infection 
and  diabetes, the risk is 3 
times greater,  or about 30% 
over a lifetime.
TB infection 
and HIV infection
(a very large risk over a lifetime)
For people with TB infection and  
HIV infection (not on HIV treatment), 
the risk is about 7% to 10% PER YEAR,  
a very large risk over a lifetime.
Figure 1.5 Risk of developing TB disease over a lifetime.
Figure showing the risk of developing TB disease over a lifetime. People with TB infection and no risk factors have about a 10% risk 
over a lifetime. For people with TB infection and diabetes, the risk is about 30% over a lifetime. For people with TB infection and HIV 
infection (not on HIV treatment) the risk is about 7% to 10% per year.
In an HIV-infected person, TB disease can develop in two ways. First, a person with LTBI can become 
infected with HIV and then develop TB disease as the immune system is weakened. Second, a person 
who has HIV infection can become infected with M. tuberculosis and then rapidly develop TB disease.
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Answers to study questions are on pages 26–30
1.15 How does being infected with both M. tuberculosis and HIV affect the 
risk for TB disease?
1.14 What conditions increase the risk that LTBI will progress to disease?
1.13 In the United States, what percentage of people with LTBI (but not HIV 
infection) usually develop TB disease over their lifetime? Select one. 
A. About 5% 
B. About 10% 
C. About 20% 
D. About 50%
Study Questions 1.12–1.15
1.12 What happens if the immune system cannot keep the tubercle bacilli 
under control and the bacilli begin to multiply rapidly? Select one. 
A. LTBI develops
B. Nontuberculous mycobacteria (NTM) infection develops 
C. TB disease develops
D. None of the above 
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Case Study 1.2
A private physician refers a 45-year-old woman to the health department 
because she was found to have LTBI as part of an employee-testing 
program.  She is overweight, with high blood pressure.  Upon further 
questioning, she reports that she has injected drugs in the past. She has 
never been tested for HIV infection.
z What conditions does this woman have that increase the risk  
that she will develop TB disease?
Answers to case study questions are on page 31
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Sites of TB Disease
TB disease can occur in different places in the body and in more than one place at the same time 
(Figure 1.6). Pulmonary TB is TB that occurs in the lungs. Most TB cases are pulmonary. Most patients 
with pulmonary TB have a cough and an abnormal chest x-ray, and they should be considered 
contagious until they meet certain criteria (see Module 5, Infectiousness and Infection Control).
Pulmonary TB occurs in the lungs. 
Extrapulmonary TB occurs in places other than the lungs, such as the larynx, the lymph nodes, 
the pleura (the membrane surrounding each lung), the brain, the kidneys, or the bones and joints. 
Extrapulmonary TB occurs more often in HIV-infected or other immunosuppressed persons, or young 
children. Some patients who have extrapulmonary TB also have pulmonary TB.
Most types of extrapulmonary TB are not considered contagious (this is discussed in Module 5, 
Infectiousness and Infection Control). However, extrapulmonary TB is often accompanied by pulmonary 
TB, which could be contagious. Of note, extrapulmonary TB that occurs in the larynx should be 
considered contagious.
Extrapulmonary TB occurs in places other than the lungs. 
Disseminated TB occurs when tubercle bacilli enter the bloodstream and are carried to all parts of the 
body, where they grow and cause disease in multiple sites. Miliary TB is a type of disseminated TB. This 
condition is rare, but life threatening. It is called miliary TB because the chest x-ray has the appearance 
of millet seeds scattered throughout the lung. Infants and young children are more likely than older 
children and adults to develop disseminated TB. 
Disseminated TB occurs when tubercle bacilli enter  
the bloodstream and are carried to all parts of the body, 
 where they grow and cause disease  in multiple sites.
Brain
Lymph node
Pleura
Lung
Spine
Kidney
Bone
Larynx
Figure 1.6 Common sites of TB disease. 
Illustration showing common sites of TB disease. These sites include the brain, larynx, 
bone, kidneys, lymph nodes, pleura, lungs, and spine.
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Classification System
The current classification system, sometimes referred to as the American Thoracic Society (ATS) classification 
system (Table 1.2), is based on the pathogenesis of TB. Thus, it is important for public health workers to be familiar 
with this system. In particular, public health workers should be aware that any patient with a classification of 3 or 
5 should be receiving treatment for TB and should be reported promptly to the local or state health department.
The current classification system 
 is based on the pathogenesis of TB.
Table 1.2–Classification System for TB.
Class Type Description
0 No TB exposure
Not infected
No history of TB exposure
Negative result to a TST or to an IGRA
1 TB exposure
No evidence of infection
History of TB exposure
Negative result to a TST or to an IGRA (done at least 8 to 10 weeks  
after exposure) 
2 TB infection 
No TB disease
Positive result to a TST or to an IGRA
Negative smears, molecular tests, and cultures
No clinical or x-ray evidence of active TB disease
3 TB, clinically active Positive culture for M. tuberculosis  OR
Positive result to a TST or to an IGRA, and clinical, bacteriological, 
 or x-ray evidence of current active TB disease
4 Previous TB disease
(not clinically active)
Medical history of TB disease
Abnormal but stable x-ray findings 
Positive result to a TST or to an IGRA
Negative smears, molecular tests, and cultures (if done)
No clinical or x-ray evidence of current TB disease
5 TB suspected Signs and symptoms of TB disease, but diagnostic evaluation  
not complete
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Study Questions 1.16–1.17
1.17 What is the classification system for TB based on? What is it used for?
1.16 What part of the body is the most common site for TB disease? 
What are some other common sites?
Answers to study questions are on pages 26–30
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Answers to Study Questions
1.1 In what year was each of the following discoveries made?  
A. TB was shown to be contagious 1865  
B. The bacterium that causes TB was discovered 1882  
C. The first drug that could kill TB bacteria was discovered 1943  
1.2 What organism causes TB?  What are four other tuberculous 
mycobacteria?  
Mycobacterium tuberculosis causes TB. M. bovis, M. africanum, M. microti,  
and M. canetti are four other tuberculous mycobacteria.
1.3 How is TB spread?  Select one.
A. TB spreads person to person through blood 
B. TB spreads person to person through the air
C. TB spreads person to person through touch
D. All of the above
The correct answer is B. TB spreads person to person through the air. When a 
person with infectious TB disease coughs, sneezes, speaks, or sings, they may 
expel tiny particles containing M. tuberculosis into the air. These particles, called 
droplet nuclei, are about 1 to 5 microns in diameter — less than 1/5000 of an inch. 
Droplet nuclei can remain suspended in the air for several hours, depending on 
the environment.
1.4 The probability that TB will be transmitted depends on what  
four factors? 
zz Infectiousness of the TB patient
zz Environment in which the exposure occurred
zz Frequency and duration of the exposure
zz Susceptibility (immune status) of the exposed individual
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1.5 What is drug-resistant TB? 
Drug-resistant TB is resistant to at least one anti-TB drug. Drug-resistant TB can  
be difficult to treat. 
1.6 What is the difference between primary and secondary drug resistance?
Primary resistance is caused by person-to-person transmission of drug-resistant 
organisms. Secondary resistance develops during TB treatment. Either the patient 
was not treated with the right TB drugs or the patient did not properly follow the 
prescribed treatment regimen.
1.7 When a person inhales droplet nuclei containing M. tuberculosis,  
where do the droplet nuclei go?  
Most of the larger droplets become lodged in the upper respiratory tract, where 
infection is unlikely to develop. However, the droplet nuclei may reach the small air 
sacs of the lung (the alveoli), where infection may begin.
1.8 After the tubercle bacilli reach the small air sacs of the lung (the alveoli), 
what happens to the tubercle bacilli?  
At first, the tubercle bacilli multiply in the alveoli and a small number enter the lymph 
nodes and bloodstream and spread throughout the body. Bacilli may reach any 
part of the body, including areas where TB disease is more likely to develop. These 
areas include the upper portions of the lungs, as well as the kidneys, the brain, and 
bone. Within 2 to 8 weeks, however, the body’s immune system intervenes, halting 
multiplication and preventing further spread in most persons. 
1.9 In people with LTBI (but not TB disease), how does the immune system 
keep the tubercle bacilli under control?  
The immune system produces special immune cells that surround the tubercle bacilli. 
The cells form a barrier shell that keeps the bacilli contained and under control.
1.10 How is LTBI detected?   
LTBI is detected by the Mantoux tuberculin skin test (TST) or an interferon-gamma 
release assay (IGRA).
Answers to Study Questions (Continued))
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1.11 What are the major similarities and differences between LTBI and TB 
disease? List characteristics of each.  
LTBI
zz Tubercle bacilli are in the body, but under control.
zz The TST and IGRA results are usually positive.
zz Usually the chest x-ray is normal.
zz Sputum smears (or smears from other specimens), molecular tests, and cultures 
are negative.
zz People with LTBI 
z Do not have symptoms (are not sick)
z Are not infectious
z Are not counted as having a case of TB
TB disease
zz Tubercle bacilli are active in the body.
zz The TST and IGRA results are usually positive.
zz Usually the chest x-ray is abnormal (if the disease is in the lungs).
zz Sputum smears (or smears from other specimens), molecular tests, cultures,  
or a combination of these tests may be positive for M. tuberculosis.  
zz People with TB disease 
z May have symptoms (are sick)
z May spread TB bacteria to others
z Are counted as having a case of TB
1.12 What happens if the immune system cannot keep the tubercle bacilli 
under control and the bacilli begin to multiply rapidly?  Select one. 
A. LTBI develops 
B. Nontuberculous mycobacteria (NTM) infection develops 
C. TB disease develops 
D. None of the above 
The correct answer is C. TB disease develops when the immune system cannot keep 
the tubercle bacilli under control. The risk that TB disease will develop is higher for 
some people than for others.
Answers to Study Questions (Continued)
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Answers to Study Questions (Continued)
1.13 In the United States, what percentage of people who have LTBI (but not 
HIV infection) usually develop TB disease over their lifetime?  Select one. 
A. About 5%
B. About 10% 
C. About 20%
D. About 50% 
The correct answer is B. In the United States, about 5% of the people who have recently 
been infected with M. tuberculosis will develop TB disease in the first year or two after 
infection. Another 5% will develop disease later in their lives. In other words, about 10% 
of all people who have LTBI will develop disease at some point. The remaining 90% will 
remain free of disease for the rest of their lives.
1.14 What conditions increase the risk that LTBI will progress to disease?  
zz Infection with HIV
zz History of untreated or inadequately treated TB disease
zz Recent TB infection (within the past 2 years)
zz Abusing drugs or alcohol or smoking cigarettes 
zz Receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) 
antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone 
per day, or immunosuppressive drug therapy following organ transplantation
zz Silicosis
zz Diabetes mellitus
zz Chronic renal failure
zz Certain types of cancer (e.g., leukemia, cancer of the head, neck, or lung)
zz Certain intestinal conditions
zz Low body weight
1.15 How does being infected with both M. tuberculosis and HIV affect the risk 
for TB disease?  
Because of their weakened immune systems, people who are infected with both 
 M. tuberculosis and HIV are much more likely to develop TB disease than people who 
are infected only with M. tuberculosis. Studies suggest that the risk of developing TB 
disease is 7% to 10% each year for people who are infected with both M. tuberculosis  
and HIV (if the HIV is not treated), whereas it is 10% over a lifetime for people infected 
only with M. tuberculosis.
In an HIV-infected person, TB disease can develop in two ways. First, a person with LTBI 
can become infected with HIV and then develop TB disease as the immune system is 
weakened. Second, a person who has HIV infection can become infected with  
M. tuberculosis and then rapidly develop TB disease.
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1.16 What part of the body is the most common site for TB disease? What 
are some other common sites?  
The lungs are the most common site for TB disease. Other common sites include:
zz Larynx
zz Lymph nodes
zz Pleura (the membrane surrounding the lungs)
zz Brain
zz Kidneys
zz Bones and joints
1.17 What is the classification system for TB based on? What is it used for?
The current classification system is based on the pathogenesis of TB. Many  
health departments and private health care providers use this system when 
describing patients.
Answers to Study Questions (Continued)
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Case Study Answers
1.1 A 30-year-old man visits the health department for a TST because he 
is required to have one before starting his new job as a health care 
worker.  He has an 18 mm positive reaction to the TST.  He has no 
symptoms of TB, and his chest x-ray findings are normal.
z Should this be considered a case of TB? Why or why not?
No.  The man described above has LTBI. He has an18 mm positive reaction to 
TST, but no evidence of TB disease.  Therefore, this is not a case of TB. 
z Should this man be considered infectious? 
No, he should not be considered infectious. This man has LTBI, not TB disease. 
People with TB infection and no evidence of TB disease are not infectious. 
1.2 A private physician refers a 45-year-old woman to the health 
department because she was found to have LTBI as part of an 
employee-testing program.  She is overweight, with high blood 
pressure. Upon further questioning, she reports that she has 
injected drugs in the past. She has never been tested for HIV 
infection.
z What conditions does this woman have that increase the risk 
that she will develop TB disease?
Drug abuse increases the risk that LTBI will progress to TB disease. This 
woman may also be at risk for HIV infection because of her injection drug 
use.  HIV is the strongest known risk factor for developing TB disease. This 
woman should be offered HIV counseling, testing, and referral. Overweight 
and high blood pressure are NOT risk factors for TB disease. 
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Notes
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